Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Su

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of Graduate Medical Education|November 1, 2018
Reality FirstChristopher Su
Open Forum Infectious Diseases|July 28, 2020
Derivation of a Model to Guide Empiric Therapy for Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Bloodstream Infection in an Endemic AreaGregory Weston, Fathima Jahufar, Nikhil Sharma, et al.
Clinical Lung Cancer|August 18, 2019
Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung CancerHaiying Cheng, H Dean Hosgood, Lei Deng, et al.
Cancers|July 14, 2023
Heterogeneous Expression of PD-L1, B7x, B7-H3, and HHLA2 in Pulmonary Sarcomatoid Carcinoma and the Related Regulatory Signaling PathwaysFeng Wang, Ayse Ece Cali Daylan, Lei Deng, et al.
Population Health Management|May 14, 2021
A Scoping Review of Behavioral Interventions Addressing Medical Financial HardshipMinal R Patel, Reshma Jagsi, Kenneth Resnicow, et al.
Clinical Genitourinary Cancer|September 10, 2021
Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotinCatherine Curran, Elio Adib, Vera Kazakova, et al.
JAMA Oncology|May 30, 2020
Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell CarcinomaPraful Ravi, Charlene Mantia, Christopher Su, et al.
BJU International|April 28, 2021
Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaborationPraful Ravi, Gregory R Pond, Leonidas N Diamantopoulos, et al.
JCO Precision Oncology|November 15, 2021
Differential Activity of PARP Inhibitors in <i>BRCA1</i>- Versus <i>BRCA2</i>-Altered Metastatic Castration-Resistant Prostate CancerFadi Taza, Albert E Holler, Wei Fu, et al.
Blood Cancer Discovery|March 9, 2022
Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19Samuel M Rubinstein, Divaya Bhutani, Ryan C Lynch, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Graduate Medical Education|November 1, 2018
Reality FirstChristopher Su
Open Forum Infectious Diseases|July 28, 2020
Derivation of a Model to Guide Empiric Therapy for Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Bloodstream Infection in an Endemic AreaGregory Weston, Fathima Jahufar, Nikhil Sharma, et al.
Clinical Lung Cancer|August 18, 2019
Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung CancerHaiying Cheng, H Dean Hosgood, Lei Deng, et al.
Cancers|July 14, 2023
Heterogeneous Expression of PD-L1, B7x, B7-H3, and HHLA2 in Pulmonary Sarcomatoid Carcinoma and the Related Regulatory Signaling PathwaysFeng Wang, Ayse Ece Cali Daylan, Lei Deng, et al.
Population Health Management|May 14, 2021
A Scoping Review of Behavioral Interventions Addressing Medical Financial HardshipMinal R Patel, Reshma Jagsi, Kenneth Resnicow, et al.
Clinical Genitourinary Cancer|September 10, 2021
Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotinCatherine Curran, Elio Adib, Vera Kazakova, et al.
JAMA Oncology|May 30, 2020
Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell CarcinomaPraful Ravi, Charlene Mantia, Christopher Su, et al.
BJU International|April 28, 2021
Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaborationPraful Ravi, Gregory R Pond, Leonidas N Diamantopoulos, et al.
JCO Precision Oncology|November 15, 2021
Differential Activity of PARP Inhibitors in <i>BRCA1</i>- Versus <i>BRCA2</i>-Altered Metastatic Castration-Resistant Prostate CancerFadi Taza, Albert E Holler, Wei Fu, et al.
Blood Cancer Discovery|March 9, 2022
Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19Samuel M Rubinstein, Divaya Bhutani, Ryan C Lynch, et al.
Pageof 1